INCY - Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

2024-04-26 13:45:12 ET

Summary

• Incyte Corporation shares have underperformed lately, but the company has shown solid growth, profitability, and increased net cash position.
• Diversification from its blockbuster drug Jakafi has been slow, but overall appeal has improved.
• The company's valuation is low, and with potential product launches and acquisitions, there is potential for future share price appreciation.

Shares of Incyte Corporation ( INCY ) have seen lackluster returns lately, and with the business announcing a bolt-on M&A move, it is time to update the investment thesis on the biotechnology firm....

For further details see: